Riptide Bioscience
Riptide Bioscience develops engineered peptides derived from host defense peptides found widely in nature. Their focus is on creating peptide-based therapeutics for cancer, inflammatory diseases, and microbial infections, especially those resistant to conventional treatments. The company advances both preclinical and early-stage clinical programs, collaborates with academic partners and government agencies, and holds patents for its engineered peptide design technologies.
Patents
What We Do
Peptide therapeutics designed for topical treatment of resistant bacterial and fungal infections, including diabetic wounds and candidiasis.
Engineered peptides targeting tumor-associated macrophages to modulate the tumor immune environment and inhibit tumor growth.
Peptide therapeutics with anti-inflammatory activity, aimed at diseases such as scleroderma, colitis, multiple sclerosis, and pulmonary fibrosis.
Development of peptides labeled with isotopes such as Gallium-68 for PET imaging of tumor-associated macrophages.
Battlefield Resuscitation
Infectious Diseases
Regenerative Medicine
Digital Health Technologies
Key People
President
Executive Vice President – Drug Design
Principal Scientist
Principal Scientist
News & Updates
Received the highest award at the Military Health Systems Research Symposium for antimicrobial research.
Study demonstrated the use of radiolabeled peptides for PET imaging of tumor-associated macrophages in a colon cancer model.
CD206-targeted peptide compared favorably with FDA-approved antifibrotic therapies in mouse models.
Peer-reviewed publication reports on efficacy of an engineered peptide in a mouse model for diabetic wound healing.
Science Translational Medicine article establishes CD206 as a novel immune checkpoint for modulating macrophages.
Antimicrobial peptides effectively treated antibiotic-resistant acne vulgaris in preclinical testing.